Genmab — April 2014
-
Roche Hldg member, Ventana, signs companion diagnostic agreement with
international biotech for antibody drug conjugate program (37.25
+0.03)Ventana Medical Systems, a member of the Roche Group, announced that
it has entered into an agreement with Genmab A/S, Copenhagen, Denmark
for the development of companion diagnostic tools for Genmab's
HuMax-TF-ADC antibody drug conjugate program. -
As part of the
agreement, Ventana will provide its expertise and services towards the
development of an immunohistochemistry companion diagnostic test for
the detection of tissue factor in patient tumor samples. The TF assay
will be developed for possible designation as the screening test in
clinical trials involving HuMax-TF-ADC.Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz2xpmqLlU7
-
-
Sukker btw. din arbejdskollega plextoren hvad laver han for tiden? lang tid siden vi har set ham
-
spændende spændende solsen
-
jep og det kan jo løfte effekten af Humax.TF-ADC når man laver randomiserede forsøg hvis man screener inden sådan at man kun får perosner ind som man ved responderer
-
Humax-TF-ADC på ASCO ? er du sindsyg. Rachel sagde til mig vi skulle være heldige hvis vi skulle se data på ASH
-
de har vel kun behandlet patienter i de meget meget lave dosis pt. ? de starter jo i de meget lavea dosis pga. giftigheden. så tror ASH er mere sandsynlig da vi så har nogle data fra lidt højere dosis og forhåbentlig nogle responser
-
-
Importantly, JNJ-61186372 effectively inhibited tumor growth in models with mutant EGFR and cMet activation, whereas single agent EGFR inhibitors were less effective. The preclinical data support the clinical development of JNJ-61186372 in patients with lung cancer and other malignancies associated with aberrant EGFR and cMET signaling.
-
We have designed a bispecific EGFR-cMet antibody (JNJ-61186372) with a unique set of mechanisms of action resulting in anti-tumor activity in the EGFR mutant setting, with or without cMet pathway activation. We have demonstrated three mechanisms of action that contribute to the activity of JNJ-61186372: 1) inhibition of ligand-induced phosphorylation of both EGFR and cMet, 2) receptor degradation in vivo, and 3) enhanced ADCC activity.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind